Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families?

Clinical Genetics

Volumn 77, Issue 3, 2010, Pages 273-279

  Panchal, S ^a   Bordeleau, L ^a   Poll, A ^b   Llacuachaqui, M ^b   Shachar, O ^a   Ainsworth, P ^c   Armel, S ^b   Eisen, A ^d   Sun, P ^b   Narod, S A ^b  

^a MOUNT SINAI HOSPITAL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

BRCA1; BRCA2; Breast cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANADA; CANCER SCREENING; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; PEDIGREE ANALYSIS; PREDICTION; PRIORITY JOURNAL;

ADULT; AGE OF ONSET; AGED; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; PEDIGREE; PENETRANCE;

EID: 77950132427     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2009.01328.x     Document Type: Article

References (14)

1. Hall JM, Lee MK, Newman B. Linkage of early-onset familial breast cancer to chromosome 17q21.1. Science 1990, 250(4988):1684-1689.
2. Wooster R, Neuhausen SL, Mangion J. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994, 265(5181):2088-2090.
3. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004, 4(9):665-676.
4. Antoniou AC, Pharoah PP, Smith P. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004, 91(8):1580-1590.
5. Daly MB, Axilbund JE, Bryant E. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 2006, 4(2):156-176.
6. Saslow D, Boetes C, Burke W. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57(2):75-89.
7. Satagopan JM, Offit K, Foulkes W. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2001, 10(5):467-473.
8. Warner E, Foulkes W, Goodwin P. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999, 91(14):1241-1247.
9. Antoniou A, Pharoah PD, Narod S. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72(5):1117-1130.
10. Chen S, Iversen ES, Friebel T. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006, 24(6):863-871.
11. Narod S, Lynch H, Conway T. Increasing incidence of breast cancer in family with BRCA1 mutation. Lancet 1993, 341(8852):1101-1102.
12. Byrnes GB, Southey MC, Hopper JL. Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Res 2008, 10((3)). 208-215
13. Gronwald J, Huzarski T, Byrski B. Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. J Med Genet 2006, 43(5):424-428.
14. Begg CB, Haile RW, Borg A. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 2008, 299(2):194-201.